Improvement in glycemic control after bariatric surgery beyond weight loss

doi:10.4239/wjd.120010

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

(26)

(29)

(0)

(15)

(384)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Jun 15, 2026; 17(6): 120010
Published online Jun 15, 2026. doi: 10.4239/wjd.120010

Table 1 Baseline characteristics of the cohort, n (%)/mean ± SD

Variable	n = 81
Sex: Female	41 (51)
Age, years (SD)	41.2 (10.5)
Medical history
Type 2 diabetes mellitus	25 (30.4)
Prediabetes	20 (24.3)
Dyslipidemia	42 (51.2)
Arterial hypertension	27 (32.9)
Type of surgery performed
Sleeve gastrectomy	81 (100)
Preoperative treatment
Insulin use	2 (2.9)
GLP-1 receptor agonist use	13 (16.0)
SGLT2 inhibitor use	7 (8.9)
Metformin use	32 (41.0)
Orlistat use	2 (2.4)
Statin use	11 (14.1)
Fibrate use	3 (3.8)
Anthropometric measurements
Weight, kg	112.2 (18.4)
Body mass index, kg/m²	40.8 (5.5)
Metabolic variables, mg/dL
Glycated hemoglobin	6.15 (1.31)
HDL cholesterol	44.4 (13.3)
LDL cholesterol	122.0 (38.8)
Triglycerides	167.6 (75.4)
Fasting plasma glucose	104.3 (14.7)
Arterial hypertension stages
Stage I	44 (53.6)
Stage II	28 (32)

HDL: High-density lipoprotein; LDL: Low-density lipoprotein; GLP-1: Glucagon-like peptide-1; SGLT2: Sodium-glucose cotransporter 2 inhibitor.

Full Size Table

Citation: Cisneros MA, Portilla N, Rincon O, Uscategui C, Alvarez M, Guzman I, Parra D, Llanos C, Romero I. Improvement in glycemic control after bariatric surgery beyond weight loss. World J Diabetes 2026; 17(6): 120010
URL: https://www.wjgnet.com/1948-9358/full/v17/i6/120010.htm
DOI: https://dx.doi.org/10.4239/wjd.120010

Cisneros MA, Portilla N, Rincon O, Uscategui C, Alvarez M, Guzman I, Parra D, Llanos C, Romero I. Improvement in glycemic control after bariatric surgery beyond weight loss. World J Diabetes 2026; 17(6): 120010 [DOI: 10.4239/wjd.120010]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.